Current status of transcatheter tricuspid valve intervention treatment_West China Medical Journal

Authors：

CAO Jingyi ,  LU Fanglin

Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, P. R. China;

Corresponding author：

LU Fanglin, Email: drlufanglin@yeah.net

Keywords：

Tricuspid regurgitation; transcatheter; interventional treatment

DOI：

10.7507/1002-0179.202207154

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In historic perspectives, tricuspid valve was considered as “forgotten valve” in the cardiovascular field. Tricuspid regurgitation (TR) is the main disease of the tricuspid valve, and the number of patients is large. TR patients have mostly treated conservatively with drugs due to high surgical mortality, so the effective treatment of TR patients is far from satisfactory. With the development of interventional technology, transcatheter tricuspid valve intervention (TTVI) is expected to become a better choice. In recent years, a number of TTVI devices have entered clinical trials and achieved good results. Due to the late development of TTVI technology and insufficient accumulation of clinical applications, there are no uniform inclusion criteria and evaluation indicators for research endpoints when conducting clinical trials. This article focuses on the introduction of different instruments of TTVI, and summarizes the current status, research progress and problems of these treatments.

Citation： CAO Jingyi, LU Fanglin. Current status of transcatheter tricuspid valve intervention treatment. West China Medical Journal, 2022, 37(9): 1377-1382. doi: 10.7507/1002-0179.202207154 Copy

1.	Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging, 2020, 21(2): 157-165.
2.	Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol, 2019, 16(9): 538-554.
3.	Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovascular Imaging, 2019, 12(3): 433-442.
4.	Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg, 2006, 132(6): 1258-1261.
5.	Yang L, Chen H, Pan W, et al. Analyses for prevalence and outcome of tricuspid regurgitation in China: an echocardiography study of 134, 874 patients. Cardiology, 2019, 142(1): 40-46.
6.	Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation, 2019, 140(3): 196-206.
7.	Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol, 2017, 69(18): 2331-2341.
8.	Arsalan M, Walther T, Smith RL 2nd, et al. Tricuspid regurgitation diagnosis and treatment. Eur Heart J. 2017, 38(9): 634-638.
9.	袁祖贻, 陈绍良. 心脏病学实践2021(全7册): 第五分册结构性心脏病. 北京: 人民卫生出版社, 2021: 75-89.
10.	Dhoble A, Zhao Y, Vejpongsa P, et al. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino), 2019, 60(1): 119-127.
11.	Dreyfus J, Ghalem N, Garbarz E, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a french nationwide database). Am J Cardiol, 2018, 122(2): 323-326.
12.	Alqahtani F, Berzingi CO, Aljohani S, et al. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc, 2017, 6(12): e007597.
13.	Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol, 2017, 70(24): 2953-2960.
14.	Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): e25-e197.
15.	Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
16.	Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol, 2018, 71(25): 2935-2956.
17.	Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 74(24): 2998-3008.
18.	LaPar DJ, Likosky DS, Zhang M, et al. Development of a risk prediction model and clinical risk score for isolated tricuspid valve surgery. Ann Thorac Surg, 2018, 106(1): 129-136.
19.	Martin AP, Bartels M, Hauss J, et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc, 2007, 39(10): 3169-3174.
20.	Xu H, Wang H, Chen S, et al. Prognostic value of modified model for end-stage liver disease score in patients undergoing isolated tricuspid valve replacement. Front Cardiovasc Med, 2022, 9: 932142.
21.	Dreyfus J, Audureau E, Bohbot Y, et al. TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J, 2022, 43(7): 654-662.
22.	Schofer J, Tiburtius C, Hammerstingl C, et al. Transfemoral tricuspid valve repair using a percutaneous mitral valve repair system. J Am Coll Cardiol, 2016, 67(7): 889-890.
23.	Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv, 2019, 12(2): 155-165.
24.	Mehr M, Taramasso M, Besler C, et al. 1-year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve registry. JACC Cardiovasc Interv, 2019, 12(15): 1451-1461.
25.	Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, 2019, 394(10213): 2002-2011.
26.	Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol, 2021, 77(3): 229-239.
27.	Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv, 2019, 12(15): 1438-1447.
28.	Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol, 2021, 77(4): 345-356.
29.	Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol, 2017, 69(14): 1795-1806.
30.	DENTI P. 4Tech-clinical outcomes and current challenges. PCR London Valves. (2017-09-26)[2022-07-01]. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2017/RAPID-FIRE-innovations-in-percutaneous-tricuspid-intervention?auth=true.
31.	Nickenig G, Weber M, Schueler R, et al. 6-month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 73(15): 1905-1915.
32.	Curio J, Demir OM, Pagnesi M, et al. Update on the current landscape of transcatheter options for tricuspid regurgitation treatment. Interv Cardiol, 2019, 14(2): 54-61.
33.	Rogers JH, Boyd WD, Bolling SF. Tricuspid annuloplasty with the Millipede ring. Prog Cardiovasc Dis, 2019, 62(6): 486-487.
34.	Pan W, Long Y, Zhang X, et al. Feasibility study of a novel transcatheter tricuspid annuloplasty system in a porcine model. JACC Basic Transl Sci, 2022, 7(6): 600-607.
35.	Asmarats L, Dagenais F, Bédard E, et al. Transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation: initial experience with the navigate bioprosthesis. Can J Cardiol, 2018, 34(10): 1370.e5-1370.e7.
36.	Navia JL, Kapadia S, Elgharably H, et al. First-in-human implantations of the navigate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv, 2017, 10(12): e005840.
37.	Hahn RT, George I, Kodali SK, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging, 2019, 12(3): 416-429.
38.	Fam NP, von Bardeleben RS, Hensey M, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv, 2021, 14(5): 501-511.
39.	Lu F, Qiao F, Lv Y, et al. A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model. Int J Cardiol, 2020, 319: 120-126.
40.	Lu FL, Ma Y, An Z, et al. First-in-Man experience of transcatheter tricuspid valve replacement with LuX-valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
41.	Lauten A, Ferrari M, Hekmat K, et al. Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J, 2011, 32(10): 1207-1213.
42.	Lauten A, Figulla HR, Unbehaun A, et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv, 2018, 11(2): e006061.
43.	Estévez-Loureiro R, Sánchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the TricValve System in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv, 2022, 15(13): 1366-1377.

1. Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging, 2020, 21(2): 157-165.
2. Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol, 2019, 16(9): 538-554.
3. Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovascular Imaging, 2019, 12(3): 433-442.
4. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg, 2006, 132(6): 1258-1261.
5. Yang L, Chen H, Pan W, et al. Analyses for prevalence and outcome of tricuspid regurgitation in China: an echocardiography study of 134, 874 patients. Cardiology, 2019, 142(1): 40-46.
6. Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation, 2019, 140(3): 196-206.
7. Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol, 2017, 69(18): 2331-2341.
8. Arsalan M, Walther T, Smith RL 2nd, et al. Tricuspid regurgitation diagnosis and treatment. Eur Heart J. 2017, 38(9): 634-638.
9. 袁祖贻, 陈绍良. 心脏病学实践2021(全7册): 第五分册结构性心脏病. 北京: 人民卫生出版社, 2021: 75-89.
10. Dhoble A, Zhao Y, Vejpongsa P, et al. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino), 2019, 60(1): 119-127.
11. Dreyfus J, Ghalem N, Garbarz E, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a french nationwide database). Am J Cardiol, 2018, 122(2): 323-326.
12. Alqahtani F, Berzingi CO, Aljohani S, et al. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc, 2017, 6(12): e007597.
13. Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol, 2017, 70(24): 2953-2960.
14. Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): e25-e197.
15. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2022, 43(7): 561-632.
16. Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol, 2018, 71(25): 2935-2956.
17. Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 74(24): 2998-3008.
18. LaPar DJ, Likosky DS, Zhang M, et al. Development of a risk prediction model and clinical risk score for isolated tricuspid valve surgery. Ann Thorac Surg, 2018, 106(1): 129-136.
19. Martin AP, Bartels M, Hauss J, et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc, 2007, 39(10): 3169-3174.
20. Xu H, Wang H, Chen S, et al. Prognostic value of modified model for end-stage liver disease score in patients undergoing isolated tricuspid valve replacement. Front Cardiovasc Med, 2022, 9: 932142.
21. Dreyfus J, Audureau E, Bohbot Y, et al. TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J, 2022, 43(7): 654-662.
22. Schofer J, Tiburtius C, Hammerstingl C, et al. Transfemoral tricuspid valve repair using a percutaneous mitral valve repair system. J Am Coll Cardiol, 2016, 67(7): 889-890.
23. Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv, 2019, 12(2): 155-165.
24. Mehr M, Taramasso M, Besler C, et al. 1-year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve registry. JACC Cardiovasc Interv, 2019, 12(15): 1451-1461.
25. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, 2019, 394(10213): 2002-2011.
26. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol, 2021, 77(3): 229-239.
27. Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv, 2019, 12(15): 1438-1447.
28. Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol, 2021, 77(4): 345-356.
29. Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol, 2017, 69(14): 1795-1806.
30. DENTI P. 4Tech-clinical outcomes and current challenges. PCR London Valves. (2017-09-26)[2022-07-01]. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2017/RAPID-FIRE-innovations-in-percutaneous-tricuspid-intervention?auth=true.
31. Nickenig G, Weber M, Schueler R, et al. 6-month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 73(15): 1905-1915.
32. Curio J, Demir OM, Pagnesi M, et al. Update on the current landscape of transcatheter options for tricuspid regurgitation treatment. Interv Cardiol, 2019, 14(2): 54-61.
33. Rogers JH, Boyd WD, Bolling SF. Tricuspid annuloplasty with the Millipede ring. Prog Cardiovasc Dis, 2019, 62(6): 486-487.
34. Pan W, Long Y, Zhang X, et al. Feasibility study of a novel transcatheter tricuspid annuloplasty system in a porcine model. JACC Basic Transl Sci, 2022, 7(6): 600-607.
35. Asmarats L, Dagenais F, Bédard E, et al. Transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation: initial experience with the navigate bioprosthesis. Can J Cardiol, 2018, 34(10): 1370.e5-1370.e7.
36. Navia JL, Kapadia S, Elgharably H, et al. First-in-human implantations of the navigate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv, 2017, 10(12): e005840.
37. Hahn RT, George I, Kodali SK, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging, 2019, 12(3): 416-429.
38. Fam NP, von Bardeleben RS, Hensey M, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv, 2021, 14(5): 501-511.
39. Lu F, Qiao F, Lv Y, et al. A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model. Int J Cardiol, 2020, 319: 120-126.
40. Lu FL, Ma Y, An Z, et al. First-in-Man experience of transcatheter tricuspid valve replacement with LuX-valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
41. Lauten A, Ferrari M, Hekmat K, et al. Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J, 2011, 32(10): 1207-1213.
42. Lauten A, Figulla HR, Unbehaun A, et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv, 2018, 11(2): e006061.
43. Estévez-Loureiro R, Sánchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the TricValve System in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv, 2022, 15(13): 1366-1377.

West China Medical Journal

Current status of transcatheter tricuspid valve intervention treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content